多倍体巨型癌细胞:在HER2向治疗中揭示了潜在的耐药性和瘤演变轴
Madhan Krishnan1, Shyamaladevi Babu1
1Faculty of Research, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, 603103, Tamilnadu, India.
研究人员发现多体巨型癌细胞 (PGCC) 积极驱动对针对HER2的抗体-药物联合体 (ADC) 的抗性. 这些适应性细胞可以再生瘤并逃避治疗,
科学领域:
- 癌症学
- 癌症生物学
- 分子疗法
背景情况:
- 针对HER2的抗体与药物联合体 (ADC) 在癌症治疗中至关重要.
- 治疗耐药性的机制仍然是一个重要的临床挑战.
- 内异质性导致治疗失败.
研究的目的:
- 阐明多体巨型癌细胞 (PGCC) 在对HER2-ADCs的耐药性中的作用.
- 了解PGCC的可塑性和再生潜力.
- 探索针对PGCC的治疗策略.
主要方法:
- 雅兹迪等人对研究结果的分析. 在"癌症信件"中.
- 对癌细胞可塑性和治疗耐药性的文献综述.
- 机械和进化解释PGCC的行为.
主要成果:
- 已确定PGCC是对HER2-ADCs耐药性的关键驱动因素.
- 它们不是衰老的,而是表观遗传的塑料储存器.
- 它们可以进入休眠状态并重新播种耐药克隆.
结论:
- PGCCs是治疗逃避的一个关键机制.
- 了解PGCC可以重新定义癌细胞的可塑性.
- 需要综合治疗方案来克服PGCC介导的耐药性.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
07:29Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
相关概念视频
Mitogens and the Cell Cycle
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
